According to Zhitong Finance App, Shengnuo Pharmaceutical-B (02257.HK) announced that on August 14, 2026, the Company and its direct wholly-owned subsidiary Shengnuo (Hong Kong) Limited (collectively, the “Plaintiff”) have filed a writ of subpoena (case number: HCA1427/2026) with the Hong Kong Special Administrative Region High Court (court) to sue several former management of the Group, including Dr. Lu Yang, Dr. Dai Xiaochang and Mr. Ye Yongji (collectively, the “Defendants”).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.